Abstract
A group of oxytocinergic neurons originating in the paraventricular nucleus of the hypothalamus and projecting to extrahypothalamic brain areas (e.g. hippocampus, medulla oblongata and spinal cord) control penile erection. Activation of these neurons by dopamine and dopamine agonists, excitatory amino acids (N-methyl-D-aspartic acid) or oxytocin itself, or by electrical stimulation leads to penile erection, while their inhibition by GABA and GABA agonists or by opioid peptides and opiate-like drugs inhibits this sexual response. The activation of oxytocinergic neurons in the paraventricular nucleus by dopamine, oxytocin and excitatory amino acids is apparently secondary to the activation of nitric oxide (NO) synthase. NO in turn activates, by a mechanism that is as yet unidentified, the release of oxytocin from oxytocinergic neurons in extrahypothalamic brain areas. Several peptide analogues of hexarelin, a growth hormone releasing peptide, also induce penile erection when injected into the paraventricular nucleus and, to a lesser extent, systemically, apparently by acting on a specific receptor to activate oxytocinergic neurons as shown for the above drugs and oxytocin. Paraventricular oxytocinergic neurons and mechanisms similar to those reported above are also involved in the expression of penile erection in physiological contexts, namely when penile erection is induced in the male by the presence of an inaccessible receptive female, which is considered a model for psychogenic impotence in man, as well as during copulation. These findings show that paraventricular oxytocinergic neurons projecting to extra-hypothalamic brain areas and to the spinal cord are a likely target for the treatment of erectile dysfunction of central origin.
Keywords: Central Oxytocinergic, Neurotransmission, Drug Target, Psychogenic, Erectile Dysfunction, N-methyl-D-aspartic acid, hippocampus, dopamine, oxytocinergic, oxytocin
Current Drug Targets
Title: Central Oxytocinergic Neurotransmission: A Drug Target for the Therapy of Psychogenic Erectile Dysfunction
Volume: 4 Issue: 1
Author(s): M. R. Melis and A. Argiolas
Affiliation:
Keywords: Central Oxytocinergic, Neurotransmission, Drug Target, Psychogenic, Erectile Dysfunction, N-methyl-D-aspartic acid, hippocampus, dopamine, oxytocinergic, oxytocin
Abstract: A group of oxytocinergic neurons originating in the paraventricular nucleus of the hypothalamus and projecting to extrahypothalamic brain areas (e.g. hippocampus, medulla oblongata and spinal cord) control penile erection. Activation of these neurons by dopamine and dopamine agonists, excitatory amino acids (N-methyl-D-aspartic acid) or oxytocin itself, or by electrical stimulation leads to penile erection, while their inhibition by GABA and GABA agonists or by opioid peptides and opiate-like drugs inhibits this sexual response. The activation of oxytocinergic neurons in the paraventricular nucleus by dopamine, oxytocin and excitatory amino acids is apparently secondary to the activation of nitric oxide (NO) synthase. NO in turn activates, by a mechanism that is as yet unidentified, the release of oxytocin from oxytocinergic neurons in extrahypothalamic brain areas. Several peptide analogues of hexarelin, a growth hormone releasing peptide, also induce penile erection when injected into the paraventricular nucleus and, to a lesser extent, systemically, apparently by acting on a specific receptor to activate oxytocinergic neurons as shown for the above drugs and oxytocin. Paraventricular oxytocinergic neurons and mechanisms similar to those reported above are also involved in the expression of penile erection in physiological contexts, namely when penile erection is induced in the male by the presence of an inaccessible receptive female, which is considered a model for psychogenic impotence in man, as well as during copulation. These findings show that paraventricular oxytocinergic neurons projecting to extra-hypothalamic brain areas and to the spinal cord are a likely target for the treatment of erectile dysfunction of central origin.
Export Options
About this article
Cite this article as:
Melis R. M. and Argiolas A., Central Oxytocinergic Neurotransmission: A Drug Target for the Therapy of Psychogenic Erectile Dysfunction, Current Drug Targets 2003; 4 (1) . https://dx.doi.org/10.2174/1389450033347190
DOI https://dx.doi.org/10.2174/1389450033347190 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Endometriosis and Gynecological Cancer
Current Women`s Health Reviews γ-Secretase: Structure, Function, and Modulation for Alzheimers Disease
Current Topics in Medicinal Chemistry Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity&#
Reviews on Recent Clinical Trials Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry Inhalation Cough Challenge
Current Respiratory Medicine Reviews Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Synthesis and Anti-Cancer Activities of Aryl Benzyl Ethers with Fluoro Substituents
Letters in Drug Design & Discovery Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
Current Pharmaceutical Biotechnology Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Pancreas Development and β-Cell Differentiation of Embryonic Stem Cells
Current Medicinal Chemistry Leishmaniasis: Current Status of Vaccine Development
Current Molecular Medicine Kinase Inhibitors in Multitargeted Cancer Therapy
Current Medicinal Chemistry Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Fatty Acids and Obesity
Current Pharmaceutical Design Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Characterization of Mutants of Sulfolobus solfataricus Signature Amidase Able to Hydrolyse R-Ketoprofen Amide
Protein & Peptide Letters Meet the Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery